Arcellx Inc (ACLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcellx Inc (ACLX) has a cash flow conversion efficiency ratio of -0.145x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.17 Million) by net assets ($402.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arcellx Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Arcellx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Arcellx Inc debt and liabilities for a breakdown of total debt and financial obligations.
Arcellx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcellx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gaztransport & Technigaz SAS
PA:GTT
|
0.372x |
|
GDS Holdings Limited
F:G40
|
0.035x |
|
NINGBO SHANSHAN GDR/A
F:OJ8
|
N/A |
|
NEXGEN ENERGY LTD CDI/1
F:6NEA
|
-0.006x |
|
JBTMarel Corp
NYSE:JBTM
|
0.026x |
|
Far East Smarter Energy Co Ltd
SHG:600869
|
0.019x |
|
Morningstar Inc
NASDAQ:MORN
|
0.090x |
|
MSA Safety
NYSE:MSA
|
0.090x |
Annual Cash Flow Conversion Efficiency for Arcellx Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Arcellx Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Arcellx Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $402.35 Million | $-210.26 Million | -0.523x | -184.74% |
| 2024-12-31 | $454.79 Million | $-83.47 Million | -0.184x | -142.92% |
| 2023-12-31 | $485.38 Million | $207.57 Million | 0.428x | +188.26% |
| 2022-12-31 | $204.95 Million | $-99.30 Million | -0.485x | -208.55% |
| 2021-12-31 | $-121.52 Million | $-54.24 Million | 0.446x | +178.71% |
| 2020-12-31 | $50.54 Million | $-28.66 Million | -0.567x | -198.90% |
| 2019-12-31 | $-32.74 Million | $-18.77 Million | 0.573x | +216.97% |
| 2018-12-31 | $14.00 Million | $-6.86 Million | -0.490x | -- |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more